/
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Adult T Acute Lymphoblastic Leukemia is an emerging landscape with 18 programs across 10 companies. 18 programs are in Phase 3.
Intelligence
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Pipeline
Analysis
94%
Small molecule
17 of 18 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 18 classified programs, each share of the total. Modality classified for 100% of 18 pipeline programs.
Analysis
1
clinical trials
Clinical Trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)